Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MAIA Biotechnology, Inc. (MAIA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Current Reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into MAIA’s clinical progress, financing transactions, and investor communications around its lead investigational therapy, ateganosine (THIO).
MAIA frequently uses Form 8-K to report material events such as private placement financings, the entry into Securities Purchase Agreements for common stock and warrants, and the intended use of proceeds to fund specific steps in its THIO-101 Phase 2 trial and broader working capital needs. These filings also incorporate press releases as exhibits, covering topics like insider open-market share purchases, initiation of the THIO-104 Phase 3 pivotal trial in advanced NSCLC, and updates on enrollment and poster presentations at conferences including SITC, AACR-NCI-EORTC, and ESMO.
Through its 8-K filings, MAIA additionally furnishes investor presentation materials and scientific posters that describe the design of its Phase 2 and Phase 3 studies, the telomere-targeting mechanism of ateganosine, and regulatory milestones such as U.S. FDA Fast Track designation for NSCLC and Orphan Drug Designations in other tumor types. These documents help investors understand how MAIA structures its clinical program, how it sequences ateganosine with checkpoint inhibitors, and how it communicates emerging data to the oncology community.
On Stock Titan, MAIA’s filings are updated in line with EDGAR, and AI-powered summaries can help explain the significance of individual reports, such as financing-related 8-Ks or other event-driven disclosures. Users can review these filings to track MAIA’s capital formation activities, clinical trial disclosures, and the formal record of press releases and presentations that shape the company’s regulatory and development narrative.
MAIA Biotechnology, Inc. reported that director Louie Ngar Yee received a grant of stock options on 12/31/2025 under the company’s 2021 Equity Incentive Plan. The grant covers 29,789 options to buy common stock at an exercise price of $1.53 per share.
The options vest 100% on the grant date and are exercisable beginning 12/31/2025, giving the director the right to purchase MAIA common shares at this fixed price. These options expire on 12/31/2035 if not exercised, so they represent a long-term equity incentive tied to the company’s future performance.
MAIA Biotechnology, Inc. reported an equity award to one of its directors. On December 31, 2025, the director received stock options to purchase 24,060 shares of MAIA common stock at an exercise price of $1.53 per share under the company’s 2021 Equity Incentive Plan. These options vest 100% on the grant date and are exercisable beginning on that date, with an expiration date of December 31, 2035. Following this grant, the director beneficially owns 24,060 derivative securities directly in the form of these options.
MAIA Biotechnology, Inc. reported an equity award to one of its directors on a Form 4 insider transaction report. On December 31, 2025, the director received 24,633 stock options under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan. These options have an exercise price of $1.53 per share, vest 100% on the grant date, and are exercisable beginning December 31, 2025, through December 31, 2035. Following this grant, the director beneficially owns 24,633 derivative securities in the form of these options, held directly.
MAIA Biotechnology director Stan V. Smith reported buying additional shares and options in the company. On December 22, 2025, he purchased 57,189 shares of MAIA common stock at $1.224 per share under a Securities Purchase Agreement and the company’s 2021 Equity Incentive Plan. After this transaction, he beneficially owns 1,421,478 shares indirectly through The Stan V. Smith Trust Dated 1993, plus additional indirect holdings of 4,580 shares in each of three separate family trusts.
He also acquired 57,189 stock options (described as warrants deemed options) with an exercise price of $1.36 per share. These options become exercisable on the six-month anniversary of the issuance date, June 22, 2026, and expire three years after the initial issuance date, on December 22, 2028. The filing notes that certain family-trust shares are held for relatives and that he disclaims beneficial ownership of those except to the extent of any pecuniary interest.
MAIA Biotechnology director reports stock and option purchases. A company director filed details of a recent transaction in MAIA Biotechnology, Inc. common stock. On December 22, 2025, the director purchased 40,849 shares of common stock at a price of $1.224 per share under a Securities Purchase Agreement and the company’s 2021 Equity Incentive Plan. Following this transaction, the director beneficially owns 151,873 shares of MAIA common stock directly.
The director also acquired 40,849 stock options (treated as warrants under the same purchase agreement and plan) with an exercise price of $1.36 per share. These options become exercisable on June 22, 2026, which is six months after the issuance date, and are scheduled to expire on December 22, 2028.
MAIA Biotechnology, Inc. director Louie Ngar Yee reported an insider purchase of common stock and related stock options. On 12/22/2025, the director acquired 81,699 shares of common stock at $1.224 per share pursuant to a Securities Purchase Agreement, bringing total directly held common shares to 1,248,888.
On the same date, the director also acquired stock options on 81,699 shares with an exercise price of $1.36 per share. These options, deemed options under the company’s 2021 Equity Incentive Plan, become exercisable on 06/22/2026 and expire on 12/22/2028. Following these transactions, the director beneficially owns 81,699 derivative securities in addition to the common stock holdings.
MAIA Biotechnology entered into a private placement with accredited investors and certain directors, selling 1,053,751 shares of common stock with matching warrants plus 179,737 director shares with matching warrants at a purchase price of $1.224 per share, for combined expected gross proceeds of approximately $2,253,896 before expenses.
The investor and director warrants become exercisable six months after issuance, carry an exercise price of 1.36 per share described as the Minimum Price under NYSE American Rule 713, and have three-year terms. Director securities are being issued under the company’s 2021 Equity Incentive Plan. MAIA plans to use the net proceeds to fund the starting cost for Step 1 of Part C of its Phase II trial THIO-101 and for working capital, with closing expected on December 18, 2025, subject to customary conditions.
MAIA Biotechnology filed an 8-K to highlight several corporate updates announced on December 11, 2025. The company reported that its leadership team has continued insider purchases of MAIA stock in 2025, signaling ongoing management engagement with the business. MAIA also announced that the first patient has been dosed in its THIO-104 Phase 3 pivotal trial evaluating its drug candidate Ateganosine as a third-line treatment for advanced non-small cell lung cancer. A third press release emphasized the momentum behind Ateganosine as this pivotal Phase 3 trial gets underway, underscoring MAIA’s focus on advancing its oncology pipeline.
MAIA Biotechnology, Inc. filed a current report to announce that it issued a new press release on December 10, 2025 titled “MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach.” The filing itself does not add financial results, but formally places the press release into the public record as an exhibit.
The company also includes a detailed caution about forward-looking statements, explaining that comments about its research programs, product candidates, regulatory timelines, manufacturing, market potential, and intellectual property involve risks and uncertainties that could cause actual results to differ materially. MAIA states it has no obligation to update these forward-looking statements except as required by law.
MAIA Biotechnology, Inc. director Stan V. Smith reported open-market purchases of the company’s common stock. On December 5, 2025, three separate transactions were reported, each for 4,580 shares of MAIA common stock at prices of
In addition, the filing shows 1,364,289 shares of MAIA common stock beneficially owned indirectly through The Stan V. Smith Trust dated 1993. The form is filed as a single-reporting-person filing and reflects Mr. Smith’s status as a director of MAIA Biotechnology.